{{Rsnum
|rsid=13120400
|Gene=ABCG2
|Chromosome=4
|position=88112375
|Orientation=plus
|GMAF=0.1382
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ABCG2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 11.5 | 37.2 | 51.3
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 0.0 | 0.7 | 99.3
| ASW | 0.0 | 14.0 | 86.0
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.9 | 99.1
| GIH | 1.0 | 24.8 | 74.3
| LWK | 0.0 | 1.8 | 98.2
| MEX | 1.7 | 25.9 | 72.4
| MKK | 0.6 | 9.6 | 89.7
| TSI | 6.9 | 33.3 | 59.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs13120400
|Name_s=
|Gene_s=ABCG2
|Feature=
|Evidence=PubMed ID:18256692
|Annotation=SNP is associated with clinical reponse to methotrexate in patients with psoriasis.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Psoriasis
|Curation Level=Curated
|PharmGKB Accession ID=PA161149201
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs13120400
|overall_frequency_n=20
|overall_frequency_d=124
|overall_frequency=0.16129
|n_genomes=14
|n_genomes_annotated=0
|n_haplomes=17
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}